Clinicopathological Significance of Long Non-Coding RNA GHET1 in Human Cancers: A Meta-Analysis

Introduction: Cancer is considered as the main public health problem and the second leading cause of morbidity and mortality worldwide. Numerous environmental-lifestyle related risk factors account for around one-third of cancer deaths. Recently, the key role of lncRNAs has been widely investigated in a variety of disorders, including cancer. The lncRNA GHET1 has been considered as an essential oncogenic lncRNA in many types of human cancers. Clinical investigations indicated that expression of lncRNA GHET1 is correlated with clinicopathological characteristics in cancer. This metaanalysis investigated the correlation between the lncRNA GHET1 expression and clinicopathological features in different types of cancers. Materials and methods: Comprehensive literature searches in PubMed, Scopus, and Web of Knowledge were conducted up to April 11, 2019. Sixteen studies were included in this meta-analysis. All statistical analyses were conducted using Stata software, version 12.0. Results: The pooled OR and 95%CIs of the sixteen relevant studies showed that over expression of lncRNA GHET1 was associated with tumor-size ≥5 cm (OR= 2.51, 95% CI: 1.89-3.33, p=0.00, I2=38.30%), positive lymph node metastasis (OR= 2.83, 95% CI: 1.78-4.52, p=0.00, I2=45.60%), advanced tumor stage (OR= 3.92, 95% CI: 2.97-5.19, p=0.00, I2=0.00%), positive distant metastasis (OR= 5.74, 95% CI: 2.58-12.77, p=0.00, I2=0.00%), advanced tumor status (OR= 2.97, 95% CI: 1.40- 6.29, p=0.01, I2=34.70%), and positive vascular invasion (OR= 2.69, 95% CI: 1.61-4.50, p=0.00, I2=29.20%). Conclusion: Taken together, the current study demonstrated that overexpression of lncRNA GHET1 is significantly associated with clinicopathological features in human cancers. Our results suggested that lncRNA GHET1 can be utilized as a prognostic biomarker in human cancer.

Download Full-text

Prognostic and clinicopathological significance of neutrophil-to-lymphocyte ratio in patients with oral cancer

Bioscience Reports ◽

10.1042/bsr20181550 ◽

2018 ◽

Vol 38 (6) ◽

Cited By ~ 6

Author(s):

Yun Yang ◽

Rongxun Liu ◽

Feng Ren ◽

Rui Guo ◽

Pengfei Zhang

Keyword(s):

Oral Cancer ◽

Meta Analysis ◽

Prognostic Significance ◽

Tumor Stage ◽

Neutrophil To Lymphocyte Ratio ◽

Advanced Tumor Stage ◽

Lymphocyte Ratio ◽

Advanced Tumor ◽

Oral Cancer Patients ◽

Clinicopathological Significance

Objectives: Many studies have examined the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) in oral cancer; however, the results are contradictory. We, therefore, conducted a meta-analysis aiming to clarify the prognostic value of the NLR in oral cancer patients. Methods: A literature search was conducted in the PubMed, Web of Science, and Embase databases. Stata version 12.0 was used for statistical analysis. Results: A total of 14 studies with 3216 patients were finally included. The results indicated that a high NLR was significantly associated with worse DFS (n=10, HR = 1.73, 95% confidence interval [CI] = 1.44–2.07, P<0.001). Similar results were observed for overall survival (OS) (n=9, HR = 1.61, 95% CI = 1.39–1.86, P<0.001). Moreover, a high NLR was also correlated with lymph node metastasis (n=7, odds ratio [OR] = 1.62, 95% CI = 1.32–1.98, P<0.001), advanced tumor stage (n=7, OR = 2.63, 95% CI = 2.12–3.25, P<0.001), T stage (n=6, OR = 3.22, 95% CI = 2.59–4.01, P<0.001), tumor differentiation (n=5, OR = 1.48, 95% CI = 1.03–2.11, P=0.033), and perineural invasion (n=4, OR = 1.83, 95% CI = 1.4–2.39, P<0.001). However, an elevated NLR was not correlated with gender. Conclusion: This meta-analysis showed that the NLR might be a potential independent prognostic factor in patients with oral cancer.

Download Full-text

Heterogeneous Periostin Expression in Different Histological Variants of Papillary Thyroid Carcinoma

BioMed Research International ◽

10.1155/2017/8701386 ◽

2017 ◽

Vol 2017 ◽

pp. 1-9 ◽

Cited By ~ 2

Author(s):

Simona Eliza Giusca ◽

Cornelia Amalinei ◽

Ludmila Lozneanu ◽

Delia Ciobanu Apostol ◽

Elena Corina Andriescu ◽

...

Keyword(s):

Epithelial Cells ◽

Tumor Stage ◽

Clinicopathological Characteristics ◽

Advanced Tumor Stage ◽

Histological Subtypes ◽

Tumor Pathology ◽

Advanced Tumor ◽

Histological Variants ◽

Tall Cell

Background. Periostin (PN) epithelial and stromal overexpression in tumor pathology has been studied according to tumor growth, angiogenesis, invasiveness, and metastasis, but a limited number of studies address PN in thyroid tumors. Aim. Our study aimed to analyze PN expression in different histological variants of PTC and to correlate its expression with the clinicopathological prognostic factors. Material and Methods. PN expression has been immunohistochemically assessed in 50 cases of PTC (conventional, follicular, oncocytic, macrofollicular, and tall cell variants), in tumor epithelial cells and intratumoral stroma. The association between PN expression and clinicopathological characteristics has been evaluated. Results. Our results show that PTC presented different patterns of PN immunoreaction, stromal PN being significantly associated with advanced tumor stage and extrathyroidal extension. No correlations were found between PN overexpression in tumor epithelial cells and clinicopathological features, except for specific histological variants, the highest risk of poor outcome being registered for the conventional subtype in comparison to the oncocytic type. Conclusions. Our study demonstrates differences in PN expression in histological subtypes of PTC. Our results plead in favor of a dominant protumorigenic role of stromal PN, while the action of epithelial PN is less noticeable.

Download Full-text

Prognostic value of lncRNA SNHG20 as a biomarker in human cancers: a systematic review and meta-analysis

10.21203/rs.3.rs-25239/v1 ◽

2020 ◽

Author(s):

Yongfeng Li ◽

Xinmiao Rui ◽

Daobao Chen ◽

Haojun Xuan ◽

Hongjian Yang ◽

...

Keyword(s):

Noncoding Rna ◽

Prognostic Value ◽

Meta Analysis ◽

Estimation Method ◽

Clinicopathological Characteristics ◽

Clinicopathological Features ◽

Tnm Stage ◽

Clinical Value ◽

Human Cancers ◽

Trim And Fill

Abstract Background: Long noncoding RNA small nucleolar RNA host gene 20 (SNHG20) is a novel oncogene and dysregulated in a variety of human cancers. It has been revealed to be associated with the clinicopathological features and prognosis. However, the prognostic value of SNHG20 in various cancers remains unclear. Therefore, we performed this meta-analysis to evaluate the relationship between SNHG20 expression and clinical outcomes in human cancers.Methods: Comprehensive literature search was performed in PubMed, Web of Science, CNKI and Wangfang databases, and eligible studies were obtained according to the inclusion and exclusion criteria. The pooled hazard ratios (HRs) and odds ratios (ORs) were applied to assess the clinical value of SNHG20 expression for overall survival (OS) and clinicopathological features.Results: A total of 16 articles including 1190 cancer patients were included in the study. The pooled results demonstrated that evaluated SNHG20 expression was positively related to a poorer OS of cancers (HR=2.36, 95%CI: 1.85-2.87, P<0.001). Subgroup analysis revealed that SNHG20 overexpression was closely related to the low OS of patients with the digestive system cancer (HR=2.92, 95%CI: 1.96-3.88, P<0.001), sample size >80 (HR=2.42, 95%CI: 1.69-3.14, P<0.001), direct HR estimation method (HR=2.65, 95%CI: 1.78-3.52, P<0.001), and median ratio as cut-off value (HR=2.21, 95%CI: 1.60-2.83, P<0.001). In addition, the pooled data also showed that SNHG20 was positively linked to lymph node metastasis (LNM) (OR=1.65, 95%CI: 1.21-2.26, P=0.002), distant metastasis (DM) (OR=1.76, 95%CI: 1.10-2.83, P=0.02), and advanced TNM stage (OR=1.79, 95%CI: 1.34-2.39, P<0.001). Moreover, the results of the trim and fill analysis confirmed the reliability of our finding. Conclusions: Upregulation of SNHG20 was associated with advanced TNM stage, worse LNM and DM, and shorter OS, suggesting that SNHG20 may serve as a biomarker for prognosis and clinicopathological characteristics in human cancers.

Download Full-text

Long non-coding RNA HEIH: a novel tumor activator in multiple cancers

Cancer Cell International ◽

10.1186/s12935-021-02272-5 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Jie-yu Sun ◽

Ming-ming Ni

Keyword(s):

Tumor Stage ◽

Advanced Tumor Stage ◽

Altered Expression ◽

Human Cancers ◽

Advanced Tumor ◽

Non Coding Rna ◽

Different Types ◽

Recent Developments ◽

Underlying Mechanisms ◽

Long Non Coding Rna

AbstractThe last decade has witnessed the altered expression levels of long non-coding RNA HEIH in different types of cancer. More than half of the HEIH studies in cancer have been published within the last two years. To our knowledge, this is the first review to discuss very recent developments and insights into HEIH contribution to carcinogenesis. The functional role, molecular mechanism, and clinical significance of HEIH in human cancers are described in detail. The expression of HEIH is elevated in a broad spectrum of cancers, and its disorder contributes to cell proliferation, migration, invasion, and drug resistance of cancer cells through different underlying mechanisms. In addition, the high expression of HEIH is significantly associated with advanced tumor stage, tumor size and decreased overall survival, suggesting HEIH may function as a prognostic biomarker and potential therapeutic target for human cancers.

Download Full-text

LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

Bioscience Reports ◽

10.1042/bsr20193532 ◽

2020 ◽

Vol 40 (8) ◽

Author(s):

Shubo Tian ◽

Jinglei Liu ◽

Shuai Kong ◽

Lipan Peng

Keyword(s):

Survival Data ◽

Poor Prognosis ◽

Meta Analysis ◽

Tumor Stage ◽

Clinicopathological Characteristics ◽

Clinicopathological Features ◽

High Expression ◽

Cochrane Library ◽

Poor Overall Survival ◽

The Cochrane Library

Abstract Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 (DLX6-AS1) is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (hazard ratio (HR) = 2.30, confidence interval (95% CI): 1.70–3.09, P<0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P<0.01), tumor size (P<0.01), lymph node metastasis (P<0.01), and distant metastasis (P<0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

Download Full-text

High BANCR expression is associated with worse prognosis in human malignant carcinomas: an updated systematic review and meta-analysis

BMC Cancer ◽

10.1186/s12885-020-07177-6 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Shixu Fang ◽

Zhou Liu ◽

Qiang Guo ◽

Cheng Chen ◽

Xixian Ke ◽

...

Keyword(s):

Noncoding Rna ◽

Smoking Status ◽

Meta Analysis ◽

Strong Relationship ◽

Tumor Stage ◽

Cochrane Library ◽

Advanced Tumor Stage ◽

China National Knowledge Infrastructure ◽

Poor Overall Survival ◽

Advanced Tumor

Abstract Background BRAF-activated noncoding RNA (BANCR) is aberrantly expressed in various tumor tissues and has been confirmed to function as a tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of BANCR in various carcinomas. Methods A comprehensive literature search of PubMed, Web of Science, EMBASE, Cochrane Library and the China National Knowledge Infrastructure (CNKI) was conducted to collect relevant articles. Results The pooled results showed a strong relationship between high BANCR expression and poor overall survival (OS) (HR (hazard ratio) =1.60, 95% confidence interval (CI): 1.19–2.15, P = 0.002) and recurrence-free survival (RFS) (HR = 1.53, 95% CI: 1.27–1.85, P < 0.00001). In addition, high BANCR expression predicted advanced tumor stage (OR (odds ratio) =2.39, 95% CI: 1.26–4.53, P = 0.008), presence of lymph node metastasis (OR = 2.03, 95% CI: 1.08–3.83, P = 0.03), positive distant metastasis (OR = 3.08, 95% CI: 1.92–4.96, P < 0.00001) and larger tumor sizes (OR = 1.63, 95% CI: 1.09–2.46, P = 0.02). However, no associations were found for smoking status (OR = 1.01, 95% CI: 0.65–1.56, P = 0.98), age (OR = 0.88, 95% CI: 0.71–1.09, P = 0.236) and sex (OR = 0.91, 95% CI: 0.72–1.16, P = 0.469). The sensitivity analysis of OS showed that the results of each publication were almost consistent with the combined results, and the merged results have high robustness and reliability. Conclusions The results showed that elevated BANCR expression was associated with unfavorable prognosis for most cancer patients, and BANCR could serve as a promising therapeutic target and independent prognostic predictor in most of cancer types.

Download Full-text

The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis

Journal of Oncology ◽

10.1155/2021/3161714 ◽

2021 ◽

Vol 2021 ◽

pp. 1-10

Author(s):

Lele Cong ◽

Hongyan Sun ◽

Miao Hao ◽

Qian Sun ◽

Yang Zheng ◽

...

Keyword(s):

Tumor Size ◽

Prognostic Value ◽

Meta Analysis ◽

Distant Metastases ◽

Tumor Stage ◽

Cochrane Library ◽

Advanced Tumor Stage ◽

Multiple Cancer ◽

Advanced Tumor ◽

Hazard Ratios

Objective. This meta-analysis was performed to identify the prognostic value of SLNCR1 in multiple cancer types. Methods. Electronic databases, including PubMed, EMBASE, and Web of Science, Cochrane Library, Medline, BioMed Central, Springer, Science Direct, and China National Knowledge Internet (CNKI), were searched for relevant studies up to August 2021, and the hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated to assess the relationship between SLNCR1 expression and overall survival (OS). Results. 12 studies with a total of 1155 patients with 9 different types of cancers were included in this meta-analysis. The pooled HR indicates that high SLNCR1 expression represented poorer prognosis of cancer (HR = 2.11, 95% CI: 1.59–2.80, I2 = 0%, P < 0.00001 ). Additionally, high SLNCR1 expression was correlated with TNM stage (odds ratio (OR): 1.72, 95% CI: 1.08–2.74, I2 = 62%, P = 0.02 ), lymph node metastasis (LNM) (OR:2.42, 95% CI: 1.61–3.64, I2 = 55%, P < 0.0001 ), and distant metastases (DM) (OR: 2.30, 95% CI: 1.50–3.55, I2 = 27%, P = 0.0002 ). However, no evidence was found for a relationship between SLNCR1 expression and clinical features such as tumor size (OR: 1.71, 95% CI: 0.93–3.14, I2 = 71%, P = 0.09 ), age (OR: 0.86, 95% CI: 0.68–1.08, I2 = 0%, P = 0.19 ), or gender (OR: 1.07, 95% CI: 0.64–1.81, I2 = 55%, P = 0.79 ). Conclusion. Our findings found that high SLNCR1 expression was associated with poor OS, advanced tumor stage, tumor size, LNM, and DM in multiple cancers, indicating that SLNCR1 may serve as a potential prognostic biomarker for cancer patients in China.

Download Full-text

Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis

BioMed Research International ◽

10.1155/2020/8828579 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Jiaqiang Li ◽

Jianchun Yin ◽

Jianhua Zhong ◽

Zhilin Yang ◽

Aifa Tang ◽

...

Keyword(s):

Human Cancer ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Progression Free Survival ◽

Positive Lymph Node ◽

Clinicopathological Features ◽

Cancer Prognosis ◽

Free Survival ◽

Patients With Cancer

Numerous studies have demonstrated that preferentially expressed antigen in melanoma (PRAME) is abnormally expressed in various solid tumours. However, the clinicopathological features and prognostic value of the PRAME expression in patients with cancer remain unclear. Accordingly, we performed a meta-analysis to accurately assess the association of the expression level of PRAME with clinicopathological features and cancer prognosis. Relevant study collection was performed in PubMed, Web of Science, and Embase until 28 February 2020. A total of 14 original studies involving 2,421 patients were included. Our data indicated that the PRAME expression was significantly associated with tumour stage ( OR = 1.99 , 95% CI: 1.48–2.67, P < 0.001 ) and positive lymph node metastasis ( OR = 3.14 , 95% CI: 1.99–4.97, P < 0.001 ). Pooled results showed that overexpression of PRAME is positively correlated with poor disease-free survival ( HR = 1.60 , 95% CI: 1.36–1.88, P < 0.001 ), progression-free survival ( HR = 1.88 , 95% CI: 1.02–3.46, P = 0.042 ), metastasis-free survival ( HR = 1.86 , 95% CI: 1.05–3.31, P = 0.034 ), and overall survival ( HR = 1.75 , 95% CI: 1.53–1.99, P < 0.001 ). In summary, these data are suggesting that PRAME is tumorigenic and may serve as a prognostic biomarker for cancer.

Download Full-text

Tumor clinicopathological characteristics and their prognostic value in mucinous colorectal carcinoma

Future Oncology ◽

10.2217/fon-2019-0342 ◽

2019 ◽

Vol 15 (35) ◽

pp. 4095-4104 ◽

Cited By ~ 1

Author(s):

Cong Luo ◽

Shuyi Cen ◽

Jieer Ying ◽

Xiaohong Wang ◽

Zhixuan Fu ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Mucinous Carcinoma ◽

Tumor Stage ◽

Clinicopathological Characteristics ◽

Rank Test ◽

Advanced Tumor Stage ◽

Advanced Tumor ◽

Poor Differentiation ◽

Cox Proportional Hazard Regression ◽

The Right

Aim: This study analyzed clinicopathological features of colorectal mucinous carcinoma and their prognostic values. Patients & method: This study enrolled 265 patients with mucinous colorectal cancer. Clinicopathological information and prognosis were reviewed retrospectively. Kaplan–Meier method, log- rank test and COX proportional hazard regression models were used. Results: In postoperative mucinous carcinoma patients (median age 56, 119 [44.9%] female), advanced tumor stage (odds ratio [OR]: 2.378; 95% CI: 1.512–3.741; p = 0.0002), poor differentiation (OR: 1.896; CI: 1.217–2.955; p = 0.0047) and right-sided tumors (OR: 2.421; CI: 1.145–5.102; p = 0.0206) were associated with shorter overall survival. Appendiceal/ileocecal cecal tumors were not different for prognosis. Conclusion: Mucinous colorectal carcinoma exhibits distinct tumor characteristics. Poor differentiation, advanced stage at presentation and the right side serve as negative prognostic factors.

Download Full-text

High BANCR may manifest worse prognosis in human malignant carcinomas: An updated systematic review and meta-analysis

10.21203/rs.2.21608/v1 ◽

2020 ◽

Author(s):

Xu Gang ◽

Shi xu Fang ◽

Zhou Liu ◽

Qiang Guo ◽

Cheng Chen ◽

...

Keyword(s):

Meta Analysis ◽

Tumor Stage ◽

Cochrane Library ◽

Advanced Tumor Stage ◽

China National Knowledge Infrastructure ◽

Poor Overall Survival ◽

Knowledge Infrastructure ◽

Advanced Tumor ◽

Non Coding Rna ◽

Promising Therapeutic Target

Abstract BackgroundBRAF-activated non-coding RNA (BANCR) was reported to be aberrantly expressed in various tumor tissues and has been confirmed to function as tumor suppressor or oncogene in many types of cancers. Considering the conflicting results and insufficient sampling, a meta-analysis was performed to explore the prognostic value of BANCR in various carcinomas.MethodsA comprehensive literature search of PubMed, Web of Science, EMBASE, Cochrane Library and the China National Knowledge Infrastructure (CNKI) was conducted to collected relevant articles.ResultsPooling results showed strong relevance of high BANCR expression and poor overall survival (OS) (HR=1.60, 95% confidence interval (CI): 1.19-2.15, P =0.002) and recurrence-free survival (RFS) (HR=1.53, 95%CI: 1.27-1.85, P <0.00001). In addition, high BANCR expression predicts advanced tumor stage (OR=2.39, 95%CI: 1.26-4.53, P =0.008), present lymph node metastasis (OR=2.03, 95%CI: 1.08-3.83, P =0.03), positive distant metastasis (OR=3.08, 95%CI: 1.92-4.96, P <0.00001) and bigger tumor size (OR: 1.63, 95%CI: 1.09-2.46, P =0.02).ConclusionsThe results showed that elevated BANCR expression was associated with unfavorable prognosis for most of cancer patients, and BANCR could be served as a promising therapeutic target and independent prognostic predictor for cancers.

Download Full-text